44 / 74 · 0:51 · Original AXON film
Semaglutide
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
Beyond body weight
Semaglutide research includes outcomes beyond body weight. The SELECT trial examined major cardiovascular events in a carefully defined group of adults. [1]
SELECT | randomized human trial
Participants had established cardiovascular disease and overweight or obesity, but no diabetes. Researchers randomly assigned semaglutide or placebo alongside standard medical care. [1]
Major cardiovascular events
The semaglutide group had fewer events in the combined outcome of cardiovascular death, nonfatal heart attack, or nonfatal stroke during follow-up. [1]
Population and product matter
This is evidence about clinical events in that population. It does not establish the same benefit for every person, formulation, or indication. Adverse effects remain part of the assessment. [1]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- Lincoff et al. (2023): Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes →SELECT population, randomized design, composite cardiovascular endpoint, and benefit versus placebo.
